Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab — a novel, patient-tailored monoclonal antibody therapy — showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped.
Click here for original story, New treatment for moderate to severe atopic dermatitis shows promising long-term results
Source: ScienceDaily